Otis W. Brawley
CIK: 0001213029
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 10, 2026LYEL
Lyell Immunopharma, Inc.
Award(A)DirectOption (right to buy)
9.3K shares- - Jun 8, 2026INCY
INCYTE CORP
Award(A)Direct1.6K shares- - Mar 19, 2026A
AGILENT TECHNOLOGIES, INC.
Award(A)Direct888 shares at avg. $111.75$99K - Mar 19, 2026A
AGILENT TECHNOLOGIES, INC.
Award(A)Direct2.2K shares at avg. $111.75$241K - Jan 12, 2026PDSB
PDS Biotechnology Corp
Award(A)DirectEmployee Stock Option (Right to Buy)
54.9K shares- - Jun 11, 2025PDSB
PDS Biotechnology Corp
Award(A)DirectEmployee Stock Option (Right to Buy)
22.7K shares- - Jun 10, 2025INCY
INCYTE CORP
Award(A)Direct2.5K shares- - May 15, 2025LYEL
Lyell Immunopharma, Inc.
Award(A)DirectOption (right to buy)
130K shares- - Mar 31, 2025LYEL
Lyell Immunopharma, Inc.
Purchase(P)Direct35.6K shares at avg. $0.56$20K - Mar 14, 2025A
AGILENT TECHNOLOGIES, INC.
Award(A)Direct812 shares at avg. $121.18$98K - Mar 14, 2025A
AGILENT TECHNOLOGIES, INC.
Award(A)Direct1.8K shares at avg. $121.18$220K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 10, 2026 |  LYEL Lyell Immunopharma, Inc. | Award(A) Option (right to buy) | 9,250 | - | - | Direct |
| Jun 8, 2026 |  INCY INCYTE CORP | Award(A) | 1,642 | - | $0 | Direct |
| Mar 19, 2026 |  A AGILENT TECHNOLOGIES, INC. | Award(A) | 888 | $111.75 | $99,234 | Direct |
| Mar 19, 2026 | A AGILENT TECHNOLOGIES, INC. | Award(A) | 2,158 | $111.75 | $241,157 | Direct |
| Jan 12, 2026 |  PDSB PDS Biotechnology Corp | Award(A) Employee Stock Option (Right to Buy) | 54,876 | - | - | Direct |
| Jun 11, 2025 | PDSB PDS Biotechnology Corp | Award(A) Employee Stock Option (Right to Buy) | 22,700 | - | - | Direct |
| Jun 10, 2025 | INCY INCYTE CORP | Award(A) | 2,518 | - | - | Direct |
| May 15, 2025 | LYEL Lyell Immunopharma, Inc. | Award(A) Option (right to buy) | 130,000 | - | - | Direct |
| Mar 31, 2025 | LYEL Lyell Immunopharma, Inc. | Purchase(P) | 35,640 | $0.56 | $19,958 | Direct |
| Mar 14, 2025 | A AGILENT TECHNOLOGIES, INC. | Award(A) | 812 | $121.18 | $98,398 | Direct |
| Mar 14, 2025 | A AGILENT TECHNOLOGIES, INC. | Award(A) | 1,819 | $121.18 | $220,426 | Direct |
1-11 of 11 transactions
About BRAWLEY OTIS W
BRAWLEY OTIS W (SEC CIK 0001213029) files insider reports with the SEC as Director of Lyell Immunopharma, Inc. (LYEL), Director of INCYTE CORP (INCY) and Director of AGILENT TECHNOLOGIES, INC. (A). Signal8 also holds filings tied to 1 other company.
Signal8 holds 9 ownership filings by BRAWLEY OTIS W, all Form 4s, filed between Mar 18, 2025 and Jun 12, 2026. Those filings report 11 transactions, from Mar 14, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on BRAWLEY OTIS W's filings is in WILMINGTON, DE.
Recent filings by BRAWLEY OTIS W
- Jun 10, 2026: Grant or award of LYEL derivative securities (Form 4, code A).
- Jun 8, 2026: Grant or award of INCY shares (Form 4, code A).
- Mar 19, 2026: Grants or awards of A shares (2 lines, Form 4, code A).
- Jan 12, 2026: Grant or award of PDSB derivative securities (Form 4, code A).
- Jun 11, 2025: Grant or award of PDSB derivative securities (Form 4, code A).
Other insiders filing for Lyell Immunopharma, Inc. (LYEL)
- Aguirre Jarrad Mattieu, Chief Medical Officer
- Shook David, Chief Medical Officer
- Seely Lynn, President and CEO
- Hill Stephen J., Chief Operating Officer
- Lee Gary K., Chief Scientific Officer
- Bulis Veronica Sanchez, VP, Corporate Controller